Location History:
- Malmö, SE (2012)
- Malmoe, SE (2015)
Company Filing History:
Years Active: 2012-2015
Title: Patrick Thomas Höjman: Innovator in Biopharmaceuticals
Introduction
Patrick Thomas Höjman is a notable inventor based in Malmoe, Sweden. He has made significant contributions to the field of biopharmaceuticals, particularly through his innovative work on interleukin-1 receptor antagonists. With a total of 2 patents, his research focuses on developing variants of polypeptides that can be used in therapeutic applications.
Latest Patents
Höjman's latest patents revolve around the invention of mutants of interleukin-1 receptor antagonists. The invention provides an isolated polypeptide comprising a variant amino acid sequence of SEQ ID NO: 1, or a fusion or derivative of said polypeptide. This polypeptide retains the biological activity of wild type IL-IRa. In one embodiment, the isolated polypeptide includes substitutions at specific amino acid positions, such as Q29K, P38Y, and others. Additionally, pharmaceutical compositions of these polypeptides are provided, along with their uses for treating diseases that can be addressed by inhibiting IL-1 receptor functions.
Career Highlights
Patrick Thomas Höjman is currently associated with Alligator Bioscience AB, a company known for its focus on developing innovative immunotherapies. His work at the company has been instrumental in advancing research in the biopharmaceutical sector.
Collaborations
Höjman collaborates with several esteemed colleagues, including Eva Maria Dahlén and Marie Asa Ingegerd Karlsson. Their combined expertise contributes to the innovative research and development efforts at Alligator Bioscience AB.
Conclusion
Patrick Thomas Höjman is a prominent figure in the field of biopharmaceuticals, with a focus on interleukin-1 receptor antagonists. His contributions through patents and collaborations highlight his commitment to advancing medical science.